Skip to main content
. 2021 Feb 18;18(8):1786–1797. doi: 10.7150/ijms.46811

Figure 3.

Figure 3

The pooled proportions of efficacy and safety outcomes (A. Overall Response; B. Complete Response; C. MRD negativity within responders; D. Relapse at last follow-up; E. Overall Survival at last follow-up; F. Grade 3-4 rates of CRS; G. NT) for RRMM with CAR-T.